Familial Adenomatous Polyposis Epidemiology Forecast Research Report 2021-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Familial Adenomatous Polyposis – Epidemiology forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This ‘Familial Adenomatous Polyposis (FAP)-Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the Familial Adenomatous Polyposis (FAP), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Familial Adenomatous Polyposis (FAP) Epidemiology

The Familial Adenomatous Polyposis (FAP) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Familial Adenomatous Polyposis (FAP) epidemiology segmented as the Prevalent Cases of Familial Adenomatous Polyposis, Diagnosed cases of Familial Adenomatous Polyposis, Etiology-specific Prevalence of Familial Adenomatous Polyposis, Type-specific Prevalence of Familial Adenomatous Polyposis.

The report includes the Incident scenario of Familial Adenomatous Polyposis (FAP) in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Familial Adenomatous Polyposis (FAP) Epidemiology

The epidemiology segment also provides the Familial Adenomatous Polyposis (FAP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total population of Familial Adenomatous Polyposis (FAP) Associated in 7MM countries was estimated to be 60.,661 cases in 2020 and expected to increase at a CAGR of 0.52% for the study period, i.e., 2018-2030.

• As per the estimates, United States has the highest incident population of Familial Adenomatous Polyposis (FAP) in 7MM.
• Among the EU5 and 7MM countries, Germany had the highest incident population of Familial Adenomatous Polyposis (FAP). On the other hand, Spain had the lowest number of cases, 1,725 cases in 2020.

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Familial Adenomatous Polyposis Market Overview at a Glance

3.1. Market Share (%) Distribution of Familial Adenomatous Polyposis in 2018

3.2. Market Share (%) Distribution of Familial Adenomatous Polyposis in 2030

4. Executive Summary of Familial Adenomatous Polyposis

5. Disease Background and Overview

5.1. Introduction

5.2. Etiology

5.3. Clinical Manifestations

5.4. Subtypes of FAP

5.5. Pathophysiology

5.6. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Patient Population of Familial Adenomatous Polyposis

6.3. Assumption and Rationale

6.4. The United States

6.4.1. Prevalent Cases of Familial Adenomatous Polyposis in the United States

6.4.2. Prevalent cases of FAP based on mutation in the United States

6.4.3. Type-specific Prevalence of Familial Adenomatous Polyposis in the United States

6.5. EU5

6.6. Germany

6.6.1. Prevalent Cases of Familial Adenomatous Polyposis in Germany

6.6.2. Prevalent cases of FAP based on mutation in Germany

6.6.3. Type-specific Prevalence of Familial Adenomatous Polyposis in Germany

6.7. France

6.7.1. Prevalent Cases of Familial Adenomatous Polyposis in France

6.7.2. Prevalent cases of FAP based on mutation in France

6.7.3. Type-specific Prevalence of Familial Adenomatous Polyposis in France

6.8. Italy

6.8.1. Prevalent Cases of Familial Adenomatous Polyposis in Italy

6.8.2. Prevalent cases of FAP based on mutation in Italy

6.8.3. Type-specific Prevalence of Familial Adenomatous Polyposis in Italy

6.9. Spain

6.9.1. Prevalent Cases of Familial Adenomatous Polyposis in Spain

6.9.2. Prevalent cases of FAP based on mutation in Spain

6.9.3. Type-specific Prevalence of Familial Adenomatous Polyposis in Spain

6.10. United Kingdom

6.10.1. Prevalent Cases of Familial Adenomatous Polyposis in the United Kingdom

6.10.2. Prevalent cases of FAP based on mutation in the United Kingdom

6.10.3. Type-specific Prevalence of Familial Adenomatous Polyposis in the United Kingdom

6.11. Japan

6.11.1. Prevalent Cases of Familial Adenomatous Polyposis in Japan

6.11.2. Prevalent cases of FAP based on mutation in Japan

6.11.3. Type-specific Prevalence of Familial Adenomatous Polyposis in Japan

7. Treatment and Management

7.1. Guidelines

7.1.1. American Society for Gastrointestinal Endoscopy Guidelines

7.1.2. European Society of Gastrointestinal Endoscopy (ESGE) guideline

8. Patient Journey

9. Case Report

10. Organizations contributing towards Familial Adenomatous Polyposis (FAP)

11. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/bz1uy1

 

 

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900